Abstract
Triple-negative breast cancer (TNBC) is a specific subtype, the most lethal and with the worst prognosis, and is prone to develop drug resistance during advanced chemotherapy. The combined application of radiotherapy and immunotherapy has gradually entered the public eye. The PD-L1 / PD-1 immune checkpoint inhibitors can enhance the local effect of radiotherapy and relieve the immunosuppressive effect in tumor patients, and the up-regulation of PD-L1 expression caused by radiotherapy also helps the checkpoint inhibitors to play a stronger effect. More patients with TNBC can gain a higher benefit from this.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
